FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma By Ogkologos - July 22, 2026 167 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-022 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated,... April 28, 2026 Caregivers Empower the Next Generation of Cancer Care August 3, 2023 ESMO Gastrointestinal Cancers Congress 2024 Munich, Germany, 26-29 June June 14, 2024 FDA Approval Likely to Change Initial Treatment for Some People with... May 2, 2025 Load more HOT NEWS Ivosidenib with Chemotherapy New Option for Some People with AML Quizartinib Approval Adds New Treatment Option for AML, Including in Older... Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed... New “Microwave Mammography” Promises to be Safer, More Accurate, and Pain-Free
